{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/pulmonary-embolism/background-information/complications/","result":{"pageContext":{"chapter":{"id":"8e279dc8-2394-5073-8866-952291c0eee6","slug":"complications","fullItemName":"Complications","depth":2,"htmlHeader":"<!-- begin field af8718c0-cc66-4923-bc17-3c9387390645 --><h2>What are the complications?</h2><!-- end field af8718c0-cc66-4923-bc17-3c9387390645 -->","summary":"","htmlStringContent":"<!-- begin item a4dc020f-77df-4a27-9b84-93754a3a47ad --><!-- begin field b7f87ef3-ba44-4890-856b-6f1db4843c94 --><ul><li><strong>Pulmonary embolism (PE) is a major cause of mortality, morbidity, and hospitalization </strong>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/pulmonary-embolism/references/\">Konstantinides, 2014</a>]<strong>.</strong><ul><li>Between 2008–2012, the number of people who died from PE went down by 30%, and in 2012, there were 2300 deaths from the condition [<a class=\"bibliography-reference internal-reference\" href=\"/topics/pulmonary-embolism/references/\">British Lung Foundation, 2019</a>].<ul><li>The mortality rate is lower in those who are haemodynamically stable and higher in those who present in cardiorespiratory arrest. Severe cases of PE can lead to collapse and/or sudden death [<a class=\"bibliography-reference internal-reference\" href=\"/topics/pulmonary-embolism/references/\">National Clinical Guideline Centre, 2012</a>]. </li><li>If untreated, the risk of death is high (studies published before 1960 reported mortalities of 23–87%) [<a class=\"bibliography-reference internal-reference\" href=\"/topics/pulmonary-embolism/references/\">Blondon et al, 2009</a>]. When treated, the risk of death is considerably lower (between 0.2–6% depending on the study) [<a class=\"bibliography-reference internal-reference\" href=\"/topics/pulmonary-embolism/references/\">Douketis et al, 1998</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/pulmonary-embolism/references/\">Douketis et al, 2007</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/pulmonary-embolism/references/\">Conget et al, 2008</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/pulmonary-embolism/references/\">Donzé et al, 2008</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/pulmonary-embolism/references/\">Jimenez et al, 2010</a>].</li><li>In people with clinically massive PE (hypotension), the estimated mortality rates are 18–65% overall and 20% following treatment [<a class=\"bibliography-reference internal-reference\" href=\"/topics/pulmonary-embolism/references/\">Belohl&aacute;vek, 2013</a>].</li></ul></li><li>An epidemiological model constructed to assess the number of venous thromboembolism (VTE) events and associated morbidity and mortality in Europe estimated that in 2004, over 317,000 deaths were related to VTE in six European countries (with a total population of 454.4 million) [<a class=\"bibliography-reference internal-reference\" href=\"/topics/pulmonary-embolism/references/\">Cohen et al, 2007</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/pulmonary-embolism/references/\">Konstantinides, 2014</a>].<ul><li>Of these cases, 34% presented with sudden fatal PE, 59% were deaths resulting from PE that remained undiagnosed during life, and 7% of the people who died early were correctly diagnosed with PE before death [<a class=\"bibliography-reference internal-reference\" href=\"/topics/pulmonary-embolism/references/\">Cohen et al, 2007</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/pulmonary-embolism/references/\">Konstantinides, 2014</a>].</li></ul></li><li>According to a report published on behalf of MBRRACE-UK (Mothers and Babies: Reducing Risk through Audits and Confidential Enquiries across the UK), VTE is one of the main direct causes of maternal death in the UK [<a class=\"bibliography-reference internal-reference\" href=\"/topics/pulmonary-embolism/references/\">Knight, 2018</a>].<ul><li>In 2014–2016, the maternal mortality from VTE during pregnancy or up to 6 weeks after the end of pregnancy in the UK was 1.39 per 100,000 pregnancies. Of the 39 women who died from VTE in the UK and Ireland, 30 died from PE during pregnancy or up to 6 weeks after pregnancy [<a class=\"bibliography-reference internal-reference\" href=\"/topics/pulmonary-embolism/references/\">Knight, 2018</a>].</li></ul></li></ul></li><li><strong>Chronic thromboembolic pulmonary hypertension (CTEPH) is a rare complication of PE, </strong>with a reported cumulative incidence of 0.1–9.1% within the first 2 years after a symptomatic PE event [<a class=\"bibliography-reference internal-reference\" href=\"/topics/pulmonary-embolism/references/\">Konstantinides, 2014</a>]. It is associated with considerable morbidity and mortality [<a class=\"bibliography-reference internal-reference\" href=\"/topics/pulmonary-embolism/references/\">Di Nisio, 2016</a>].<ul><li>In people with CTEPH, emboli are replaced over months or years by fibrous tissue, leading to chronic obstruction of the pulmonary arterial vasculature, progressive increases in pulmonary arterial pressure, and, if untreated, right heart failure.</li><li>Inadequate anticoagulation, large thrombus mass, residual thrombi, and recurrence of VTE may contribute to the development of CTEPH. </li></ul></li></ul><!-- end field b7f87ef3-ba44-4890-856b-6f1db4843c94 --><!-- end item a4dc020f-77df-4a27-9b84-93754a3a47ad -->","topic":{"id":"322088c5-226e-5f2b-9fd2-2e2c0678abc1","topicId":"6b233aab-5318-4abb-96fa-1877e917ef2c","topicName":"Pulmonary embolism","slug":"pulmonary-embolism","lastRevised":"Last revised in October 2020","chapters":[{"id":"7d60ce89-0a3c-5336-a5d4-755eb5bfb2cd","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"99df9a07-7867-5283-b7c8-4589c8f6e029","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"b4da2d8a-f835-512f-b218-660b7fc61806","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"c60f44ed-a5f4-566e-8718-a289b4d4e969","slug":"changes","fullItemName":"Changes"},{"id":"42a750f4-f134-55a8-a654-9c23ac2a3bfd","slug":"update","fullItemName":"Update"}]},{"id":"b8001d19-4cf2-5db4-b8b5-f082fbff4fbd","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"52656989-9cf4-597c-8118-0fadcb887b21","slug":"goals","fullItemName":"Goals"},{"id":"cdd140ec-bd30-59e9-9777-c921159ea664","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"c32413cc-9382-5aaa-b03b-95ed29a1b360","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"c1a308a6-aa46-578f-98f1-ed7872474fb4","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"1629cec2-329a-5273-a313-15a0783d5b22","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"d4860e1f-9b8b-5f49-bdb5-fb068af327ab","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"9e6802a1-b9c3-5fa9-b632-ef9712c1724b","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"588bb6e5-794e-52df-9953-d91254204285","slug":"definition","fullItemName":"Definition"},{"id":"e2fbb90b-8419-52d9-bfd2-a9eab621be3b","slug":"prevalence","fullItemName":"Prevalence"},{"id":"ad38abd5-7668-59b3-828a-9edd427dbdd5","slug":"pathophysiology","fullItemName":"Pathophysiology"},{"id":"9b45f610-d957-50a3-9e85-019832acd145","slug":"risk-factors","fullItemName":"Risk factors"},{"id":"8e279dc8-2394-5073-8866-952291c0eee6","slug":"complications","fullItemName":"Complications"},{"id":"8be5980d-145d-5d9c-b255-f057579ce868","slug":"prognosis","fullItemName":"Prognosis"}]},{"id":"c07c0850-0c27-58a8-96a8-96051968c076","fullItemName":"Diagnosis","slug":"diagnosis","subChapters":[{"id":"1db70c8e-a80c-587a-8e5e-5adf28878587","slug":"when-to-suspect","fullItemName":"When to suspect"},{"id":"a71fc8ea-c1d7-5be5-a888-41b834fdca93","slug":"differential-diagnosis","fullItemName":"Differential diagnosis"}]},{"id":"f18a5246-939d-51ce-adb5-f6538871345a","fullItemName":"Management","slug":"management","subChapters":[{"id":"42f102a2-ceab-531f-880e-4075895d9c12","slug":"suspected-pulmonary-embolism","fullItemName":"Scenario: Suspected pulmonary embolism"},{"id":"cd66b55b-908e-56dc-811f-db55be20b710","slug":"confirmed-pulmonary-embolism","fullItemName":"Scenario: Confirmed pulmonary embolism"}]},{"id":"6ae8a494-48a2-5d60-b0f8-39dd5e02489b","fullItemName":"Prescribing information","slug":"prescribing-information","subChapters":[{"id":"8b812684-b06c-50e2-86d7-f012b792c674","slug":"parenteral-anticoagulants","fullItemName":"Parenteral anticoagulants"},{"id":"f367e7b5-6b1b-5f42-9d57-a8edab35855f","slug":"oral-anticoagulants","fullItemName":"Oral anticoagulants"}]},{"id":"c1bef62c-2c5a-5588-af53-1a0b4b26d3e3","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"3941fd8f-10fb-53d4-8dc1-3835ad3ca3e3","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"26fc4bf9-2995-5109-9f1e-3ba9ad3dd2dd","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"f1b2f1f8-81e2-5a3c-b454-2f63f66f6235","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"83fd7f66-6953-54a6-b55f-8d2858a82e97","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"bd9e363f-a674-594d-8bb9-8779d385e06a","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"20c76427-9b00-5da0-bd68-6486385780f2","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"96a22dd0-587f-5051-8263-acea49ba216b","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"9e6802a1-b9c3-5fa9-b632-ef9712c1724b","slug":"background-information","fullItemName":"Background information"},"subChapters":[]}}},"staticQueryHashes":["3666801979"]}